These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 11002232

  • 1. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
    Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside JW, Moss TH, Brada M, Whaley JB, Stenning SP.
    Cancer; 2000 Sep 15; 89(6):1359-70. PubMed ID: 11002232
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):501-8. PubMed ID: 15145169
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
    Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI.
    N Engl J Med; 1998 Jul 02; 339(1):21-6. PubMed ID: 9647875
    [Abstract] [Full Text] [Related]

  • 5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.
    Orv Hetil; 2009 Oct 18; 150(42):1937-44. PubMed ID: 19812012
    [Abstract] [Full Text] [Related]

  • 6. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
    Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI, Southwest Oncology Group.
    J Clin Oncol; 2003 Jul 01; 21(13):2466-73. PubMed ID: 12829664
    [Abstract] [Full Text] [Related]

  • 7. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2001 Jun 15; 91(12):2440-6. PubMed ID: 11413536
    [Abstract] [Full Text] [Related]

  • 8. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
    O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL.
    Int J Radiat Oncol Biol Phys; 1995 Oct 15; 33(3):663-73. PubMed ID: 7558957
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients.
    Singhal D, Witham TF, Germanwala A, Flickinger JC, Schiff D, Kondziolka D.
    Can J Neurol Sci; 2002 May 15; 29(2):147-53. PubMed ID: 12035835
    [Abstract] [Full Text] [Related]

  • 14. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F, Groupe d'Etude des Lymphomes de l'Adulte.
    J Clin Oncol; 2007 Mar 01; 25(7):787-92. PubMed ID: 17228021
    [Abstract] [Full Text] [Related]

  • 15. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL).
    Cancer; 2006 Jan 01; 106(1):136-45. PubMed ID: 16331635
    [Abstract] [Full Text] [Related]

  • 16. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH, Delgado DJ.
    Cancer; 2003 Dec 01; 98(11):2402-9. PubMed ID: 14635075
    [Abstract] [Full Text] [Related]

  • 17. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, Bosi A.
    Cancer; 2005 Mar 01; 103(5):970-7. PubMed ID: 15666323
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.